Yang Jiezuan, Zhang Zhengliang, Pang Caihong, Cao Dan, Yan Dong, Fan Jun
The First Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease, Hangzhou 310003, China.
Department of Laboratory Medicine, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
Transl Oncol. 2024 Oct;48:102071. doi: 10.1016/j.tranon.2024.102071. Epub 2024 Aug 3.
Chemokines play a crucial role in the pathogenesis of patients with hepatocellular carcinoma (HCC). The expression levels of interferon-γ-induced protein-10 (CXCL10) and macrophage inflammatory protein-3α (MIP-3a) were investigated to clarify their clinical significance in HCC. The protein levels of CXCL10 and MIP-3a in the serum of 105 HBV-associated HCC patients, 50 patients with liver cirrhosis (LC), 50 patients with chronic hepatitis B (CHB) and 50 healthy donors (HC) were detected by liquid chip technology (Luminex) or ELISA. In addition, their mRNA levels were also determined in liver cancer and adjacent cancer tissue (paracancer; ParaCa) from 65 HCC patients. The online database UALCAN was used to analyze the association between CXCL10 and pathological manifestations of liver cancer. In addition, the diagnostic value of CXCL10/MIP-3a and AFP in HCC patients was determined by analyzing the Receiver Operating Characteristic Curve (ROC). The protein concentrations of CXCL10 and MIP-3a were significantly higher in the HCC group than in the LC, CHB and HC groups. CXCL10 in sera and liver cancer tissues is significantly positively correlated with ALT, but no significance between CXCL10 in ParaCa tissues and sera-ALT. Their mRNA is significantly higher in cancer tissues than in ParaCa tissues. The areas under the ROC curve of CXCL10, MIP-3a, CXCL10 and MIP-3a combined and AFP were 0.9169, 0.9261, 0.9299 and 0.7880, respectively. Elevated chemokines CXCL10 and MIP-3a in HCC patients may be associated with the clinical manifestation of HCC and could be a potential molecular marker for prognostic evaluation or a therapeutic target for HCC.
趋化因子在肝细胞癌(HCC)患者的发病机制中起关键作用。研究了γ干扰素诱导蛋白10(CXCL10)和巨噬细胞炎性蛋白3α(MIP-3α)的表达水平,以阐明它们在HCC中的临床意义。采用液相芯片技术(Luminex)或酶联免疫吸附测定(ELISA)检测105例乙肝相关HCC患者、50例肝硬化(LC)患者、50例慢性乙型肝炎(CHB)患者和50例健康供者(HC)血清中CXCL10和MIP-3α的蛋白水平。此外,还测定了65例HCC患者肝癌组织及癌旁组织(癌旁;ParaCa)中它们的mRNA水平。利用在线数据库UALCAN分析CXCL10与肝癌病理表现之间的关联。此外,通过分析受试者工作特征曲线(ROC)确定CXCL10/MIP-3α和甲胎蛋白(AFP)对HCC患者的诊断价值。HCC组中CXCL10和MIP-3α的蛋白浓度显著高于LC组、CHB组和HC组。血清和肝癌组织中的CXCL10与谷丙转氨酶(ALT)显著正相关,但癌旁组织中的CXCL10与血清ALT之间无显著相关性。它们的mRNA在癌组织中显著高于癌旁组织。CXCL10、MIP-3α、CXCL10与MIP-3α联合以及AFP的ROC曲线下面积分别为0.9169、0.9261、0.9299和0.7880。HCC患者中趋化因子CXCL10和MIP-3α升高可能与HCC的临床表现有关,可能是预后评估的潜在分子标志物或HCC的治疗靶点。